In an analysis of Patient Reported Outcome (PRO) data (VFQ-25 and OSDI questionnaires) from the Randomized Control Pivotal Trial (RCT) of iStent inject®, subjects undergoing iStent inject® plus cataract surgery reported greater vision-related quality of life improvement than cataract surgery alone.
Maintaining ocular comfort remains an unmet medical need in glaucoma treatment. This study published in AJO (Samuelson TW, Singh IP, Williamson BK, Falvey H, Lee WC, Odom D, McSorley D, Katz LJ. Quality of Life in Primary Open-Angle Glaucoma and Cataract: An Analysis of VFQ-25 and OSDI from the iStent inject® Pivotal Trial. Am J Ophthalmol. 2021 Mar 15:S0002-9394(21)00120-3. doi: 10.1016/j.ajo.2021.03.007. Epub ahead of print. PMID: 33737036) suggests that not only does iStent inject® not compromise ocular comfort, but it actually may also improve it by reducing medication dependence.
This is the first evidence from a MIGS RCT showing benefit in patients’ QOL due to improved ocular symptoms and vision-related activities resulting from lowering medication burden.
FURTHER INFORMATION:
Glaukos and iStent inject®
